15-Deoxy-Δ¹²,¹⁴ prostaglandin J₂ reduces the formation of atherosclerotic lesions in apolipoprotein E knockout mice.
AIM: 15-deoxy-Δ¹²,¹⁴ prostaglandin J₂ (15d-PGJ₂) is a ligand of peroxisome proliferator-activated receptor γ (PPARγ) having diverse effects such as the differentiation of adipocytes and atherosclerotic lesion formation. 15d-PGJ₂ can also regulate the expression of inflammatory mediators on immune ce...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2011-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC3189199?pdf=render |
| _version_ | 1818290863488368640 |
|---|---|
| author | Takahiro Seno Masahide Hamaguchi Eishi Ashihara Masataka Kohno Hidetaka Ishino Aihiro Yamamoto Masatoshi Kadoya Kaoru Nakamura Ken Murakami Satoaki Matoba Taira Maekawa Yutaka Kawahito |
| author_facet | Takahiro Seno Masahide Hamaguchi Eishi Ashihara Masataka Kohno Hidetaka Ishino Aihiro Yamamoto Masatoshi Kadoya Kaoru Nakamura Ken Murakami Satoaki Matoba Taira Maekawa Yutaka Kawahito |
| author_sort | Takahiro Seno |
| collection | DOAJ |
| description | AIM: 15-deoxy-Δ¹²,¹⁴ prostaglandin J₂ (15d-PGJ₂) is a ligand of peroxisome proliferator-activated receptor γ (PPARγ) having diverse effects such as the differentiation of adipocytes and atherosclerotic lesion formation. 15d-PGJ₂ can also regulate the expression of inflammatory mediators on immune cells independent of PPARγ. We investigated the antiatherogenic effect of 15d-PGJ₂. METHODS: We fed apolipoprotein (apo) E-deficient female mice a Western-type diet from 8 to 16 wk of age and administered 1 mg/kg/day 15d-PGJ₂ intraperitoneally. We measured atherosclerotic lesions at the aortic root, and examined the expression of macrophage and inflammatory atherosclerotic molecules by immunohistochemical and real-time PCR in the lesion. RESULTS: Atherosclerotic lesion formation was reduced in apo E-null mice treated with 15d-PGJ₂, as compared to in the controls. Immunohistochemical and real-time PCR analyses showed that the expression of MCP-1, TNF-α, and MMP-9 in atherosclerotic lesions was significantly decreased in 15d-PGJ₂ treated mice. The 15d-PGJ₂ also reduced the expression of macrophages and RelA mRNA in atherosclerotic lesions. CONCLUSION: This is the first report 15d-PGJ₂, a natural PPARγ agonist, can improve atherosclerotic lesions in vivo. 15d-PGJ₂ may be a beneficial therapeutic agent for atherosclerosis. |
| first_indexed | 2024-12-13T02:34:56Z |
| format | Article |
| id | doaj.art-7799c92dc83f4395a0c4535b5de79ea6 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-13T02:34:56Z |
| publishDate | 2011-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-7799c92dc83f4395a0c4535b5de79ea62022-12-22T00:02:25ZengPublic Library of Science (PLoS)PLoS ONE1932-62032011-01-01610e2554110.1371/journal.pone.002554115-Deoxy-Δ¹²,¹⁴ prostaglandin J₂ reduces the formation of atherosclerotic lesions in apolipoprotein E knockout mice.Takahiro SenoMasahide HamaguchiEishi AshiharaMasataka KohnoHidetaka IshinoAihiro YamamotoMasatoshi KadoyaKaoru NakamuraKen MurakamiSatoaki MatobaTaira MaekawaYutaka KawahitoAIM: 15-deoxy-Δ¹²,¹⁴ prostaglandin J₂ (15d-PGJ₂) is a ligand of peroxisome proliferator-activated receptor γ (PPARγ) having diverse effects such as the differentiation of adipocytes and atherosclerotic lesion formation. 15d-PGJ₂ can also regulate the expression of inflammatory mediators on immune cells independent of PPARγ. We investigated the antiatherogenic effect of 15d-PGJ₂. METHODS: We fed apolipoprotein (apo) E-deficient female mice a Western-type diet from 8 to 16 wk of age and administered 1 mg/kg/day 15d-PGJ₂ intraperitoneally. We measured atherosclerotic lesions at the aortic root, and examined the expression of macrophage and inflammatory atherosclerotic molecules by immunohistochemical and real-time PCR in the lesion. RESULTS: Atherosclerotic lesion formation was reduced in apo E-null mice treated with 15d-PGJ₂, as compared to in the controls. Immunohistochemical and real-time PCR analyses showed that the expression of MCP-1, TNF-α, and MMP-9 in atherosclerotic lesions was significantly decreased in 15d-PGJ₂ treated mice. The 15d-PGJ₂ also reduced the expression of macrophages and RelA mRNA in atherosclerotic lesions. CONCLUSION: This is the first report 15d-PGJ₂, a natural PPARγ agonist, can improve atherosclerotic lesions in vivo. 15d-PGJ₂ may be a beneficial therapeutic agent for atherosclerosis.http://europepmc.org/articles/PMC3189199?pdf=render |
| spellingShingle | Takahiro Seno Masahide Hamaguchi Eishi Ashihara Masataka Kohno Hidetaka Ishino Aihiro Yamamoto Masatoshi Kadoya Kaoru Nakamura Ken Murakami Satoaki Matoba Taira Maekawa Yutaka Kawahito 15-Deoxy-Δ¹²,¹⁴ prostaglandin J₂ reduces the formation of atherosclerotic lesions in apolipoprotein E knockout mice. PLoS ONE |
| title | 15-Deoxy-Δ¹²,¹⁴ prostaglandin J₂ reduces the formation of atherosclerotic lesions in apolipoprotein E knockout mice. |
| title_full | 15-Deoxy-Δ¹²,¹⁴ prostaglandin J₂ reduces the formation of atherosclerotic lesions in apolipoprotein E knockout mice. |
| title_fullStr | 15-Deoxy-Δ¹²,¹⁴ prostaglandin J₂ reduces the formation of atherosclerotic lesions in apolipoprotein E knockout mice. |
| title_full_unstemmed | 15-Deoxy-Δ¹²,¹⁴ prostaglandin J₂ reduces the formation of atherosclerotic lesions in apolipoprotein E knockout mice. |
| title_short | 15-Deoxy-Δ¹²,¹⁴ prostaglandin J₂ reduces the formation of atherosclerotic lesions in apolipoprotein E knockout mice. |
| title_sort | 15 deoxy δ¹² ¹⁴ prostaglandin j₂ reduces the formation of atherosclerotic lesions in apolipoprotein e knockout mice |
| url | http://europepmc.org/articles/PMC3189199?pdf=render |
| work_keys_str_mv | AT takahiroseno 15deoxyd1214prostaglandinj2reducestheformationofatheroscleroticlesionsinapolipoproteineknockoutmice AT masahidehamaguchi 15deoxyd1214prostaglandinj2reducestheformationofatheroscleroticlesionsinapolipoproteineknockoutmice AT eishiashihara 15deoxyd1214prostaglandinj2reducestheformationofatheroscleroticlesionsinapolipoproteineknockoutmice AT masatakakohno 15deoxyd1214prostaglandinj2reducestheformationofatheroscleroticlesionsinapolipoproteineknockoutmice AT hidetakaishino 15deoxyd1214prostaglandinj2reducestheformationofatheroscleroticlesionsinapolipoproteineknockoutmice AT aihiroyamamoto 15deoxyd1214prostaglandinj2reducestheformationofatheroscleroticlesionsinapolipoproteineknockoutmice AT masatoshikadoya 15deoxyd1214prostaglandinj2reducestheformationofatheroscleroticlesionsinapolipoproteineknockoutmice AT kaorunakamura 15deoxyd1214prostaglandinj2reducestheformationofatheroscleroticlesionsinapolipoproteineknockoutmice AT kenmurakami 15deoxyd1214prostaglandinj2reducestheformationofatheroscleroticlesionsinapolipoproteineknockoutmice AT satoakimatoba 15deoxyd1214prostaglandinj2reducestheformationofatheroscleroticlesionsinapolipoproteineknockoutmice AT tairamaekawa 15deoxyd1214prostaglandinj2reducestheformationofatheroscleroticlesionsinapolipoproteineknockoutmice AT yutakakawahito 15deoxyd1214prostaglandinj2reducestheformationofatheroscleroticlesionsinapolipoproteineknockoutmice |